SAB Biotherapeutics Inc. Company Profile
NASDAQ: SABSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 8, 11:08 AM ET
SAB Biotherapeutics at a glance
SAB Biotherapeutics Inc. (NASDAQ: SABS) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Miami Beach, FL. SAB Biotherapeutics is led by Mr. Samuel J. Reich and employs about 86 people. The company's shares have traded publicly since 2021.
At a market capitalization of $266.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001833214, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does SAB Biotherapeutics do?
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Business description based on the company's public filings.
Company information
- Legal name
- SAB Biotherapeutics Inc.
- Ticker
- NASDAQ: SABS
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Samuel J. Reich
- Employees
- 86
- Headquarters
- 777 W 41st St., Miami Beach, FL, United States
- Phone
- 305 845 2813
- Website
- sab.bio
- IPO year
- 2021
- Market cap
- $266.59M
- SEC CIK
- 0001833214
- Latest annual report
- 10-K · Mar 9, 2026
Companies similar to SAB Biotherapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LXEOLexeo Therapeutics Inc. | 3.21 | -3.02% | $263.50M | vs SABS |
| IKTInhibikase Therapeutics Inc. | 1.88 | -3.09% | $262.33M | vs SABS |
| XFORX4 Pharmaceuticals Inc. | 2.74 | -2.49% | $271.66M | vs SABS |
| SRZNSurrozen Inc. | 23.79 | -5.39% | $279.62M | vs SABS |
| STROSutro Biopharma Inc. | 15.25 | +4.02% | $252.86M | vs SABS |
| FATEFate Therapeutics Inc. | 2.05 | -4.65% | $245.63M | vs SABS |
| LCTXLineage Cell Therapeutics Inc. | 0.9619 | +1.51% | $243.27M | vs SABS |
| PALIPalisade Bio Inc. | 1.40 | -5.74% | $243.11M | vs SABS |